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Kappa Opioid Receptor-Induced Aversion Requires p38
MAPK Activation in VTA Dopamine Neurons
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The endogenous dynorphin- opioid receptor (KOR) system encodes the dysphoric component of the stress response and controls the
risk of depression-like and addictionbehaviors; however, themolecular andneural circuitmechanisms are not understood. In this study,
we report that KOR activation of p38 MAPK in ventral tegmental (VTA) dopaminergic neurons was required for conditioned place
aversion (CPA) inmice. Conditional genetic deletion of floxed KOR or floxed p38MAPKby Cre recombinase expression in dopaminer-
gic neurons blocked place aversion to the KOR agonist U50,488. Selective viral rescue by wild-type KOR expression in dopaminergic
neurons of KOR/ mice restored U50,488-CPA, whereas expression of a mutated form of KOR that could not initiate p38 MAPK
activation did not. Surprisingly, while p38MAPK inactivation blocked U50,488-CPA, p38MAPKwas not required for KOR inhibition
of evoked dopamine release measured by fast scan cyclic voltammetry in the nucleus accumbens. In contrast, KOR activation acutely
inhibitedVTAdopaminergic neuron firing, and repeated exposure attenuated the opioid response. This adaptation to repeated exposure
wasblockedby conditional deletionof p38MAPK,whichalsoblockedKOR-induced tyrosinephosphorylationof the inwardly rectifying
potassium channel (GIRK) subunit Kir3.1 in VTA dopaminergic neurons. Consistent with the reduced response, GIRK phosphorylation
at this amino terminal tyrosine residue (Y12) enhances channel deactivation. Thus, contrary to prevailing expectations, these results
suggest that  opioid-induced aversion requires regulation of VTA dopaminergic neuron somatic excitability through a p38 MAPK
effect on GIRK deactivation kinetics rather than by presynaptically inhibiting dopamine release.
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Introduction
Stress exposure has profound effects on mood and drug abuse
risk (Kendler et al., 1999; Brady and Sinha, 2005). Uncontrolled,
sustained stressful experiences increase depressive and anxiety
disorders in humans and in animal models of these behaviors
(Neumann et al., 2011; Kormos and Gaszner, 2013). Stress expo-
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Significance Statement
Kappa opioid receptor (KOR) agonists have the potential to be effective, nonaddictive analgesics, but their therapeutic utility is
greatly limited by adverse effects on mood. Understanding how KOR activation produces dysphoria is key to the development of
better analgesics and to defining how the endogenous dynorphin opioids produce their depression-like effects. Results in this
study show that the aversive effects of  receptor activation required arrestin-dependent p38 MAPK activation in dopamine
neurons but did not require inhibition of dopamine release in the nucleus accumbens. Thus, contrary to the prevailing view,
inhibition of mesolimbic dopamine release does not mediate the aversive effects of KOR activation and functionally selective 
opioids that do not activate arrestin signaling may be effective analgesics lacking dysphoric effects.
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sure also increases the rewarding valence of drugs of abuse, pro-
motes escalation of addictive drug consumption, and stimulates
relapse in abstinent individuals (Brady and Sinha, 2005;Mantsch
et al., 2015). Developing proresilience medications based on an
understanding of how stress controls these behaviors has the po-
tential for a novel therapeutic advance. Key to this understanding
is the analysis of how stress-evoked release of neurotransmitters
affects neural circuit physiology and decision-making processes.
A series of recent studies indicate that stress exposure produces its
dysphoric, anxiogenic, and proaddictive effects through the acti-
vation of extrahypothalamic cortocotrophin releasing factor,
which releases the endogenous dynorphin opioid neuropeptides
in brain (Land et al., 2008; Mantsch et al., 2015). Dynorphin
selectively activates  opioid receptors (KOR), and rodents
treated with  receptor antagonists or genetically lacking either
prodynorphin or KOR have reduced immobility in forced swim
assays (typical of antidepressant drug actions), reduced social
avoidance behaviors following repeated social defeat, reduced
escalation of psychostimulant self-administration, and redu-
ced reinstatement of extinguished ethanol or cocaine self-
administration (Bruchas et al., 2010; Van’t Veer and Carlezon,
2013; Lalanne et al., 2014). Recent clinical studies confirm that
drugs having KOR antagonist activity significantly reduce de-
pressive symptoms in humans with treatment-resistant depres-
sion and reduce nicotine consumption in dependent individuals
(Ehrich et al., 2015; Saxon et al., 2015).
Pharmacological activation of KOR in humans evokes reports
of dysphoria and anxiety similar to those detected in rodentmod-
els (Pfeiffer et al., 1986;Millan, 1990; Vortherms andRoth, 2006).
At the circuit level, KOR activation in the serotonergic neurons of
dorsal raphe nucleus (DRN), the dopaminergic neurons of the
ventral tegmental area (VTA), and neurons of the nucleus ac-
cumbens (NAc) have been implicated in the aversive properties
of the stress response (Bruchas et al., 2010; Van’t Veer and Car-
lezon, 2013). These results suggest that dynorphin regulates
mood by controlling serotonergic and dopaminergic inputs to
the NAc, but these circuit mechanisms are not yet clear. At the
molecular level, KOR activation stimulates Gi/o protein signaling
that reduces neuronal activity by increasing potassium conduc-
tance, decreasing voltage activated calcium conductance, and in-
hibiting transmitter vesicle release (Bruchas et al., 2010). In
addition, sustained KOR activation recruits arrestin-dependent
signaling, which activates p38 mitogen-activated protein kinase
(MAPK) signaling (Chavkin et al., 2014). Pharmacological
inhibition of p38 MAPK, genetic block of KOR-dependent
p38 MAPK activation by G-protein-coupled receptor kinase 3
(GRK3) deletion, or cell-specific deletion of p38 MAPK in se-
rotonergic neurons blocks stress-induced aversion (Bruchas et
al., 2011; Chavkin et al., 2014). The separation between the re-
ceptor signaling pathways controlling G-protein-mediated re-
sponses and arrestin-mediated responses have important
implications for drug development in general, but within the
KOR system specifically, these findings predict that a G-biased
KOR agonist would have analgesic efficacy without the dysphoric
properties of conventional KOR agonists (Chavkin, 2011). Find-
ing a noneuphorigenic (thus nonaddictive) opioid analgesic has
been a central goal of opioidmedicinal chemistry for100 years,
but the prediction that G-biased KOR agonists that do not acti-
vate p38 MAPK signaling would not be dysphoric requires that
we understand how activation of KOR either pharmacologically
or by stress-induced dynorphin release produces dysphoria.
Di Chiara and Imperato (1988) originally noted that KOR
agonists inhibited dopamine release measured by in vivo micro-
dialysis in the striatum, and suggested that dysphoria was a con-
sequence of reduced dopamine tone. This hypothesis was
consistent with the prevailing view that euphoric effects of addic-
tive drugs resulted froman elevation of dopamine tone (Wise and
Bozarth, 1982). Subsequent studies by Schultz et al. (1998) pro-
vided a more nuanced view of dopamine function, suggesting
that dopamine actually provides a “reward-prediction error sig-
nal,” rather than a simple “reward” signal. Thus, how KOR inhi-
bition of dopamine release contributes to dysphoria is not clear,
and reconciling our understanding of KOR activation of p38
MAPK mechanisms and regulation of dopamine release seems
necessary to understand how stress-induced dysphoria is en-
coded in brain. In the present study, we measured KOR regula-
tion of dopamine release using fast-scan cyclic voltammetry
(FSCV), used Cre recombinase-dependent conditional genetic
deletion of KOR or p38MAPK in VTA dopamine neurons, and
used conditioned place aversion behavioral assays to assess the
mechanisms underlying dynorphin/KOR dependent dysphoria.
Materials andMethods
Animals. Male C57BL/6 mice (Charles River) 50 d old were used and
given ad libitum access to food and water. Conditional knock-out of
p38 in dopaminergic neurons was achieved using p38 floxed
(Mapk14lox/) mice on C57BL/6 background as previously described
(Bruchas et al., 2011) and crossing them with mice that express Cre
recombinase under the control of the dopamine transporter (DAT,
Slc6a3Cre/), a unique marker for dopaminergic neurons (Zhuang et al.,
2005). Global gene deletion of KOR (Oprk1/) on C57BL/6 back-
ground was accomplished as previously described (Hough et al., 2000).
In some instances, conventional KOR gene knock-out mice were bred to
also carry the DAT-Cre transgene. Conditional gene knock-out of KOR
was achieved using a floxed KOR line generated by the Institut Clinique
de la Souris, in which exon 1 of KORwas flanked by loxP sites. This exon
was then selectively excised in dopaminergic neurons by crossing to the
DAT-Cre line and in serotonergic neurons by crossing with the ePet-Cre
line (Scott et al., 2005; Zhuang et al., 2005). All animal procedures
were approved by the University of Washington Institutional Animal
Care and Use Committee.
Genotyping.Genotypingwasperformedaspreviouslydescribed (Bruchas
et al., 2011). PCR screening was performed using the following primers: A3
(5-ATGAGATGCAGTACCCTTGGAGACCAGAAG-3) andA4 (5-AGC
CAGGGCTATACAGAGAAAAACCCTGTG-3) for the floxed and wild-
type () p38 alleles, giving bands of 230 and 180 bp, respectively. Primers
A1 (5-CCACAGAAGAGATGGAGCTATATGGATCTC-3) and A4 were
used to detect the null p38 allele as a 420 bp PCR product. TheDAT-Cre
and ePet-Cre transgenes were detected using 5-AGCGTTCGAACG
CACTGATTTCG-3 and 5-CGCCGTAAATCAATCGATGAGTTG-3,
yielding a 330 bp band. The ROSA26-yellow fluorescent protein (ROSA-
YFP) reporter gene was screened for with 5-AAGACCGCGAAG
AGTTTGTC-3, 5-AAAGTCGCTCTGAGTTGTTAT-3, and 5-GGA
GCGGGAGAAATGGATATG-3, giving a 320 bp EYFP and 600 bp wild-
type band. For screening of global KOR knock-outs, the wild-type KOR
allele was amplified using 5-AATTGTCTTTTGGCCACTGC-3 and 5-
GTTGGTTGCGGTCTTCATCT-3 giving a 510 bp band, whereas the null
KOR knock-out allele yielded a 450 bp band when screened in a separate
reaction with 5-AGGAAGCAAAAAGCCTCTCC-3 and 5-CTCGT
CCTGCAGTTCATTCA-3. For the floxed KOR mice, 5-GCACCA
AAGTCAGGGAAGGT-3 and 5CAGGGCATATACTCTTCTCGCT-3
were used to screen for thewild-type and floxedKORalleles, giving bands of
317 and 427 bp, respectively.
Stereotaxic injection. Mice were anesthetized with isoflurane and
mounted on a model 1900 stereotaxic alignment system (David Kopf
Instruments). For VTA injections, a 32 gauge needle with a 45 degree
beveled tip (Hamilton) was lowered bilaterally (anteroposterior 3.30
mm, mediolateral 0.30 mm from bregma) and 0.5 l was injected at
dorsoventral4.70 to 4.75 mm and at4.40 to 4.45 mm from bregma.
For DRN injections, a 25 gauge needle with beveled tip (Hamilton) was
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lowered unilaterally (anteroposterior4.65 mm, mediolateral 0.00 mm
from bregma) and 1 l was injected at dorsoventral 3.90 to 4.00 mm
from bregma. Injection locations were confirmed via postmortem
immunohistochemistry.
Vector design and production. Lenti-KOR and Lenti-KOR(S369A)
(Lenti-KSA) were developed and produced as previously described
(Land et al., 2008). AAV-DIO KOR-GFP and AAV-DIO KSA-GFP were
developed using the AM/CBA-DIO-poly vector (Cardin et al., 2009). Rat
KOR-GFP or KSA-GFP was subcloned into the AAV-DIO vector using
AgeI andNotI in the reverse coding orientation so that expression would
only be driven in the presence of Cre recombinase under the chicken
-actin promoter.
After confirming sequence fidelity, HEK293T cells were transfected
with 10g AAV and 20g pDG1 vector per 10 cmplate. Three days after
transfection, cells were harvested and subjected to three freeze–thaw cy-
cles. The supernatant was transferred to a Beckman tube containing a
40% sucrose cushion and spun at 27,000 rpm overnight at 4°C. Pellets
were resuspended in CsCl at a density of 1.37 g/ml and spun at 5000 rpm
overnight at 4°C. The following day, 1 ml CsCl fractions were run on an
agarose gel, and genome-containing fractions were selected and spun
again at 5000 rpm overnight at 4°C. The 1 ml fractions were collected
again, and genome containing fractions were dialyzed overnight. The
filtered solution was transferred to a Beckman tube and spun at 27,000
rpm overnight at 4°C. The pellet (containing purified AAV) was resus-
pended in 100 l 1HBSS.
Conditioned place preference (CPP). Mice were trained in a balanced
three-chamber apparatus consisting of chambers of equal size with hor-
izontal or vertical stripes, and a third smaller chamber in the center. The
paradigm consisted of tests on day 1 and four and training on days 2 and
3. On test days, the mice were placed in the center chamber and then
allowed to roam freely through all three chambers for 30min. Time spent
in each chamber was recorded with a video camera (Canon DC310) and
analyzed using Ethovision (Noldus). On training days, mice received
saline vehicle (10 ml/kg, i.p.) while restricted to one chamber in the
morning and the prototypical  opioid agonist U50,488 (2.5–5.0 mg/kg
at 10 ml/kg, i.p.) or cocaine (15 mg/kg at 10 ml/kg, s.c.) in the other
chamber in the afternoon. The drug-paired chamber was assigned based
on the day 1 pretest to ensure that the average time spent in each chamber
was the same for all groups. The final preference score was determined
based on the difference in the amount of time spent in the drug-paired
chamber on the day 4 post-test and the day 1 pretest. All mice were
handled once or twice a day for 4 d the week before the day 1 pretest. For
cocaineCPP experiments, locomotor activitywas recorded and analyzed.
U50,488 locomotor experiments. Following the 4 dU50,488CPA exper-
iment, on days 5 and 6, a subset ofmice were injectedwith either saline or
U50,488 (10 mg/kg) and allowed to roam the CPP chamber freely. To
allow for a within-subjects comparison, injections were administered in
an alternating fashion such that half of themice in a given cohort received
each injection on a given day.
Tail-flick analgesia.Mice were held while the tip of their tail was sub-
merged in 52 1°C water, and the tail withdrawal latencies were timed.
Each mouse was exposed twice: once as a baseline and a second time 30
min after administration of 15 mg/kg U50,488.
Immunohistochemistry. Mice were anesthetized with sodium pento-
barbital (120 mg/kg, i.p.) and intracardially perfused with ice-cold PBS
and 4% PFA. Brains were stored overnight in 4% PFA, then cryopro-
tected in 30% sucrose (w/v) in phosphate buffer (PB) solution. At least
48 h later, brains were sliced at 30 m using a microtome (Leica). Slices
were stored at 4°C in PB with 0.1% sodium azide. VTA and DRN slices
were then taken andwashed for 3 10min inPBSbefore blocking in PBS
containing 5% normal goat serum and 0.3% Triton X-100. Slices were
then incubated for 36–48 h in blocking solution containing pairs of the
following primary antibodies: chicken anti-tyrosine hydroxylase (1:1000,
AB9702, Millipore), rabbit anti-KOR (1:1000, from an affinity purified
1.32 g/ml stock) (Drake et al., 1996), chicken anti-GFP (1:3000,
AB13970, Abcam), mouse anti-tyrosine hydroxylase (1:500, T1299,
Sigma), mouse anti-tryptophan hydroxylase (1:500, T0678, Sigma), and
mouse anti-GAD67 (1:1000, MAB5406, Millipore). In addition, we used
a rabbit polyclonal antibody generated against the phosphorylated-Tyr
12 residue of KIR 3.1 (7.5 g/ml, GIRKp) (Ippolito et al., 2005; Lemos et
al., 2012). The peptide sequence used to generate GIRKp is unique based
on a blast search of the mouse genome, and GIRKp-ir was not evident in
Kir3.1/ mice (Ippolito et al., 2005). Standard immunohistochemical
procedures were performed to obtain pY12-KIR 3.1 (GIRKp-ir) and
yellow-fluorescent protein (YFP-ir) (Abcam, chicken polyclonal
ab13970) staining. Slices were then washed for 6  15 min in PBS and
incubated in blocking solution containing Alexa-488 and Alexa-555 (1:
500, Invitrogen) tagged to IgG of the appropriate species. The slices were
thenwashed for 3 10min in PBS and 2 10min in PB. Sliceswere then
mounted onto Superfrost Plus slides (Fisher) with Vectashieldmounting
media and sealed with nail polish for microscopy. All slices were imaged
at the W.M. Keck Center for Advanced Studies in Neural Signaling (Se-
attle) on either a Leica SL confocal or a Nikon Upright with QImaging
Camera.
GIRKp-ir quantification. For comparisons of GIRKp-ir from different
behavioral treatment groups, two or three animals for each group were
perfused, sectioned, and processed in parallel. Imaging of sections from
animals exposed to different treatments was done at the same time with
the samemicroscope and camera settings. As different rounds of staining
often yield different immunoreactive (ir) intensities, images from each
treatment group displayed in this study came from the same round of
staining. The patterns of GIRKp-ir seen in the VTA across treatment
groups were similar to that previously reported in the dorsal raphe
(Lemos et al., 2012). The selectivity for dopamine neurons of the DAT-
Cre driver present in our control and p38 CKODAT mice has been
shown previously (Zhuang et al., 2005; Bruchas et al., 2011); and as such,
we used YFP staining as a proxy for dopaminergic phenotype to directly
compare Cre-expressing neurons in control and conditional knock-out
mice.We quantifiedGIRKp-ir in putative dopamine neurons of the VTA
using Photoshop software to calculate the percentage of YFP-ir-positive
cells also displaying GIRKp-ir (i.e., colocalization) in fields imaged at
20magnification. Cells were considered positive for the protein if the
intensity of the immunoreactivity was 1 SD above the average back-
ground pixel intensity for that slice. Images used for quantification were
not adjusted for brightness or contrast. Cell counts and quantification
were performed by an observer blind to treatment and genotype.
Rotarod. Mice were placed on a 4-cm-wide rotating rod (Rotarod,
San Diego Instruments), which accelerated from 4 to 40 rpm over 4
min. The latency to fall off of or clasp onto the rotating rod was
recorded.
In vitro voltammetry. Mice were rapidly decapitated, the brain was
dissected, and slices were prepared as previously described (Lemos et al.,
2012).Microelectrodes were fabricated by pulling carbon fiber through a
glass pipette using a Sutter P-97 puller to form a glass seal. The fiber was
then cut to 	100–120 m past the seal. The potential at the working
electrode was held at0.4 V versus an Ag/AgCl reference electrode, then
ramped to 1.3 V and then back to0.4 V at 400 V/s at a rate of 10 Hz. A
single biphasic electric pulse was applied using a platinum/iridium par-
allel bipolar stimulating electrode (FHC) at 300–500 A to evoke dopa-
mine release. Each animal contributed 1–3 slices to each group. Each slice
was counted as an individual replicate.
In vivo voltammetry.Mice were anesthetized with 1.5 g/kg urethane.
Sixty minutes later, depth of anesthesia was confirmed and mice were
mounted on a model 900 stereotaxic alignment system (David Kopf
Instruments). A carbon fiber microelectrode (manufactured as de-
scribed above) was implanted in the NAc (anteroposterior 1.52 mm,
mediolateral1.15 mm, dorsoventral3.9 to 4.3 mm from bregma)
and a silver chloride reference electrode was implanted contralater-
ally. Bipolar parallel stimulation electrodes (Plastics One) were im-
planted either in the medial forebrain bundle (MFB) (anteroposterior
2.40 mm, mediolateral 1.10 mm, dorsoventral 4.5 to 5.20 mm
from bregma) or the pedunculopontine tegmental area (PPTg) (an-
teroposterior 0.68 mm from, mediolateral 0.70 mm, dorsoven-
tral2.50 to 3.20 mm from bregma). For MFB recordings, a stimulus
of 6 pulses was applied at 30 Hz and 300 A to evoke dopamine
release. For PPTg recordings, a stimulus of 30 pulses was applied at 60
Hz and 150 A. Stimuli were applied every 300 s. After 60 min, mice
were injected with U50,488 (5 mg/kg, i.p.) and recording continued
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for 60 min. The six stimuli before drug
administration were averaged to define
the baseline. At the end of each experiment,
the remaining urethane was injected into the
mouse before inducing an electrolytic lesion
at the site of the working electrode. The
mouse was then intracardially perfused with
ice-cold PBS 4% PFA. After cryoprotection
with 30% sucrose, brains were sliced at 40
m and then stained with cresyl violet to
confirm the recording site (and, for PPTg
stimulation experiments, the stimulation
site) as previously described (Ehrich et al.,
2014).
In vivo electrophysiology. As previously de-
scribed (Zweifel et al., 2011), microdrives
were fabricated in house using 16-channel
electrode interface boards (EIB-16; Neural-
ynx) and tetrodes made from 0.00099-inch-
diameter tungsten wire (California Fine
Wire). Mice were stereotaxically implanted
into the VTA using coordinates x 
 3.25
mm from bregma, y 
 0.05 mm from mid-
line, and z 
 4.5 mm from dura. Two
weeks following recovery, mice were
screened for putative dopamine neurons.
During recording sessions, data were ac-
quired by connecting mice to a 16-channel
Medusa Preamplifier. Signals were filtered at
300–5000 Hz using a RZ5 Signal Processor
(Tucker-Davis Technologies). Tetrodes were
lowered daily in 	40 m increments until
unit activity was observed. For all recording
sessions, mice were habituated in the record-
ing chamber for 10 min before session start.
Once recording began, a 10 min baseline pe-
riod was acquired followed by administra-
tion of drugs. Putative dopamine neurons
from N 
 4 control and N 
 5 p38 MAPK
CKOmice were identified by firing rate (12
Hz) and by sensitivity to quinpirole (a reduc-
tion in firing rate to 50% of baseline).
Quinpirole-sensitive firing rates were calcu-
lated from a 10 min window starting 3 min
after injection. Once dopaminergic cells
were identified, cell activity was recorded
over 4 consecutive days. One day following
identification of quipirole-sensitive neu-
rons, activity was recorded during a 10 min
baseline followed by two successive injec-
tions of saline and 50 min of additional re-
cording following each injection for a total
recording session of 110 min. On the second,
third, and fourth day, mice were adminis-
tered saline (50 min recording) followed by
U50,488 (5 mg/kg). For nor-binaltor-
phimine dihydrochloride (norBNI) pretreatment, five mice were in-
jected with norBNI (10 mg/kg) 50 min before U50,488 injection.
Single units were isolated by cluster analysis using Offline Sorter
software (Plexon), and clustered waveforms were analyzed using
MATLAB software (The MathWorks).
Drugs. () U50,488H, () U69,593, nor-binaltorphimine dihydro-
chloride (norBNI), and cocaine hydrochloride were provided by the
National Institute of Drug Abuse Drug Supply Program. SB203580
was obtained fromMillipore. Quinpirole and urethane were obtained
from Sigma-Aldrich. Sodium pentobarbital and Beuthanasia
Special-D were obtained from University of Washington Medical
Center Drug Services. All drugs were dissolved in saline for use in vivo
or aCSF for use in vitro.
Analysis.Data were compiled inMicrosoft Excel, and data analyses were
performed inPrism5.01 forWindows (GraphPad). CPPdatawere analyzed
by Student’s t test or one-way ANOVAwhere appropriate. Locomotor, tail-
flick analgesia, and voltammetry data were analyzed using two-way
repeated-measures ANOVA. For in vivo voltammetry, the last six stimuli of
each treatment (baselinevsU50,488)wereaveraged for eachanimal, and this
average was used for statistical comparisons. For in vitro voltammetry, the
last four stimuliof each treatment (baseline, SB203580/vehicle,U69,593, and
norBNI) were averaged for each slice. When ANOVA revealed statistical
significance, Bonferroni post hoc analyses were applied where appro-
priate; in certain cases, Bonferroni post hoc analyses were applied after
no interaction was seen to confirm negative results. Data are pre-
sented as mean  SEM. Significance was set at p  0.05.
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Figure 1. Conditional knock-out of KOR from either dopaminergic or serotonergic neurons blocks U50,488-CPA, but only KOR
CKO fromdopaminergic neuronsblocks inhibitionof dopamine release.a, Conditionedplace aversion followingU50,488 (5mg/kg)
was evident inwild-type and KOR lox/lox littermates butwas blocked by conditional KOR gene deletion in either dopaminergic (CKO
KOR DAT) or serotonergic (CKO KOR Pet) neurons. Place preference scores showed that both CKO KOR DAT and CKO KOR Pet lack
U50,488 CPA relative to KOR lox/lox littermates (n
 9–22). *p 0.05 (Bonferroni post hoc after one-way ANOVA). **p 0.01
(Bonferroni post hoc after one-way ANOVA). b, Representative image showing analysis of slice FSCV data. Bottom, Heat map
represents current generated by oxidation and reduction at the site of the working electrode during application of the triangle
waveform. Top, Current timeplot shows evokeddopamine release anduptake. Orangedashed line indicatesmagnitudeof peak
current, which was recorded for each stimulation event (marked by arrow: 1 pulse, 300–500A). Inset, Cyclic voltammagram
from the timeof peak current confirms that the current recordedwas inducedby oxidation and reduction of dopamine. Calibration:
2 nA, 0.1 V. c, Left, Diagram depicting placement of bipolar stimulating electrode (red) and recording electrode (blue) during slice
FSCV experiments (modified from Paxinos and Franklin, 2008). Right, Representative traces showing raw current responses of
KOR lox/lox, KOR CKO DAT, and KOR CKO Pet to 1MU69,593 (green) and 1M norBNI (purple). Calibration: 4 nA, 2 s. Arrow indicates
stimulation timing. d, Change from baseline locally stimulated peak [DA] during baseline and following administration of 1M
U69,593 and 1M norBNI. Each drug was bath-applied during the interval signified by the bar. e, Summary data of percentage
change in [DA] from baseline shows that KOR CKO DAT significantly blocked U69,593-induced inhibition of evoked dopamine
release relative to KOR lox/lox littermates, whereas inhibition of DA releasewas unaltered in KOR CKO Pet (n
 4 or 5 slices from 2 or
3 animals). ***p 0.001 (Bonferroni post hoc after one-way ANOVA). All graphs represent data as mean SEM.
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Results
KOR activation in both dopamine and serotonin neurons is
required for place aversion
To compare the roles of KOR activation in dopamine neurons
and serotonin neurons in aversion, we generated a conditional
knock-out of KOR in dopaminergic (DAT-Cre-expressing) neu-
rons and serotonergic (ePet-Cre-expressing) neurons using a
Cre-induced excision of a floxed KOR allele (KOR CKODAT and
KOR CKOPet, respectively). Male KORlox/lox littermate controls
from both colonies showed CPA to U50,488, whereas neither
KOR CKODAT nor KOR CKOPet showed
U50,488 CPA (Fig. 1a; one-way ANOVA,
F(2,40)
 7.338, p 0.01; post hoc analyses:
KORlox/lox vs KOR CKODAT, t(40) 

2.340, p  0.05; KORlox/lox vs KOR
CKOPet, t(40) 
 3.623, p  0.01). These
results demonstrated that selective genetic
ablation of KOR within either class of
neurons was sufficient to block U50,488
CPA.
KORCKO from dopaminergic neurons,
but not serotonergic neurons, blocks
inhibition of dopamine signaling
Prior studies concluded that the aver-
sion response to KOR activation was
caused by inhibition of dopamine re-
lease in the NAc (Shippenberg et al.,
1993), which requires expression of
KOR by dopamine neurons (Chefer et
al., 2013; Tejeda et al., 2013). To deter-
mine whether KOR CKOPet blocked
U50,488 CPA by altering the response of
NAc dopamine signaling to KOR activa-
tion, we used FSCV to record evoked
dopamine release from midbrain slices
containing the NAc (Fig. 1b). The KOR
agonist U69,593 (1 M) produced ro-
bust inhibition of evoked dopamine in
midbrain slices from KORlox/lox and
KOR CKOPet mice (52.7% and 54.5%
below baseline, respectively). This inhi-
bition was reversed upon washout or
addition of the KOR antagonist norBNI
(1 M) (Fig. 1c– e). In contrast, evoked
dopamine response in slices from KOR
CKODAT showed no significant change
in the presence of either drug (Fig.
1c– e). A two-way repeated-measures
ANOVA showed a significant interac-
tion (F(2,11) 
 18.10, p  0.001). Fur-
ther, post hoc analyses demonstrated
that both KOR lox/lox (t(11) 
 4.309,
p  0.001) and KOR CKOPet (t(11) 

4.242, p  0.001) mice showed signifi-
cant inhibition of dopamine release rel-
ative to KOR CKODAT mice after
U69,593. Thus, while KOR excision
from either dopamine neurons or sero-
tonin neurons blocked CPA, KOR exci-
sion from serotonin neurons blocked
CPA despite continued inhibition of
evoked NAc dopamine release.
KOR activation in the VTA is required for place aversion
Local inactivation of KOR by stereotaxic injection of the long-
acting KOR antagonist norBNI (2.5g/l) into the VTA blocked
U50,488 CPA (Fig. 2a; unpaired t test, t(7) 
 3.306, p  0.05,
compared with mice injected with an equal volume of saline in
VTA). norBNI has previously been demonstrated to block
KOR activation up to 21 d after administration (Bruchas et al.,
2007b). This result demonstrated that activation of KORs
f
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Figure 2. KOR activation within the VTA is both necessary and sufficient for U50,488-induced CPA. a, Local inactivation of KOR
by bilateral stereotaxic injection of norBNI into the VTA blocked U50,488 (5 mg/kg) induced CPA. Place preference scores for WT
mice injected with either saline or 2.5g/l norBNI in the VTA before U50,488 conditioning (n
 8). *p 0.05, saline versus
norBNI (t test). b, U50,488 produced significant place aversion in wild-type (KOR/) mice, but not in KOR/ knock-outmice.
Right, KOR/mice were injected with lenti-KOR, lenti-KSA, or lenti-eGFP in the VTA before U50,488 CPA. Lenti-KOR in the VTA
significantly restored U50,488 CPA, whereas neither lenti-KSA nor lenti-eGFP did. Left, *p 0.05 (t test). Right, *p 0.05
(Bonferroni post hoc analysis after one-way ANOVA). n
 11–19. c, U50,488 (10 mg/kg) significantly reduced locomotor activity
compared with saline injection in wild-type KOR/mice, but not in KOR/ or in mice receiving lenti-viral injections in VTA
(n
 6–11). ***p 0.001 (Bonferroni post hoc analysis after two-way ANOVA). x-axis labels are the same groups as in b. d,
Similarly, U50,488 significantly reduced tail-withdrawal latencies comparedwith saline injection in wild-type KOR/mice, but
not in KOR/ or in mice receiving lenti-viral injections in VTA. Withdrawal latencies were recorded before and 30 min after 15
mg/kg U50,488 (n
 11–19). ***p 0.001 (Bonferroni post hoc after two-way ANOVA). x-axis labels are the same groups as in
b. e, In contrast, latency to tail-flick was significantly increased by 15mg/kg U50,488 in KOR/mice injected with lenti-KOR in
DRN (n
 13). ***p 0.001 (paired t test). f, Representative IHC images showing restoration of KOR immunoreactivity (red)
in TH-ir (green) neurons of the VTA after injection of lenti-KOR or lenti-KSA into the VTA of KOR/mice, but not after injection
of lenti-KOR into the DRN. Note the presence of double-labeled neurons (yellow) in uninjected KOR/ and in sections from
KOR/mice injectedwith either lenti-KOR or lenti-KSA in VTA. Bottom-right inset (red rectangle), Location of the section of the
parabrachial pigmented nucleus of the VTA fromwhich images were taken (modified from Paxinos and Franklin, 2008).
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within the VTA was necessary for U50,488 CPA. To assess
sufficiency, we next injected KOR/ (Oprk1/) mice with a
lentiviral vector directing expression of the wild-type KOR
(lenti-KOR) (viral design as previously described; Land et al.,
2008). Lenti-KOR injection in the VTA selectively restored the
aversive properties of KOR activation (one-way ANOVA,
F(2,33) 
 5.140, p  0.05) (Fig. 2b). In contrast, uninjected
KOR/ or mice injected lentivirus encoding enhanced green
fluorescent protein alone (lenti-eGFP) did not develop
U50,488 CPA (Fig. 2b). A different group of KOR/ mice
were injected with a lentiviral vector directing expression of
KOR with a serine to alanine substitution at serine 369 (lenti-
KSA). Phosphorylation of KOR by GRK3 at serine 369 is nec-
essary for arrestin-dependent activation of p38 MAPK while
allowing for arrestin-independent signaling, such as activa-
tion of extracellular signal-regulated kinase (ERK1/2) (Bru-
chas et al., 2006). KOR/mice expressing lenti-KSA (t(33)

2.891, p  0.05) did not develop U50,488 aversion (Fig. 2b).
KOR/ mice injected with lenti-KOR in the DRN as a posi-
tive control also showed a restoration of U50,488 CPA (data
not shown, one-sample t test, p  0.01, t(14) 
 3.538), repli-
cating our previous findings (Land et al., 2008).
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Figure 3. KOR activation selectively in VTA dopamine neurons is sufficient for KOR CPA. a, Schematic represents the design of AAV-DIO viral construct, alongwith inversion of KOR-GFP/KSA-GFP
gene and excision of loxp/lox2722 sites in the presence of Cre.b, Representative IHC images showing DIO-KSA-GFP selectively expressed in VTA TH-ir neurons in DAT Cre/ but not DAT/ animals
after VTA injection: red represents TH-r; green represents GFP-ir; yellow represents colabeling. c, Cell counts after VTA injection of DIO-KOR-GFP or DIO-KSA-GFP show a significant increase in cells
double-labeled with TH-ir and GFP-ir in DAT Cre/ animals relative to DAT/ littermates (n
 7–16). ***p 0.001 (Bonferroni post hoc after two-way ANOVA). d, U50,488-CPAwas selectively
restored after injection of DIO-KOR-GFP into the VTA of DAT Cre/, KOR/mice, but not after injection of DIO-KSA-GFP (n
 14–17). **p 0.01 (t test).
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Systemic injection of 10 mg/kg U50,488 induces locomotor
hypoactivity, an effect that is mediated by KOR actions at sub-
stantia nigra dopamine neurons (Schnur andWalker, 1990). For
2 d following the CPA post-test, a subset of animals were alter-
nately injected with either saline or U50,488 (10 mg/kg, i.p.) and
allowed to freely explore the CPP chambers. Two-way ANOVA
showed a significant interaction (F(4,37)
 8.480, p 0.0001), and
KOR/ mice showed a significant inhibition in locomotor ac-
tivity after U50,488 relative to saline (t(37) 
 7.259, p  0.001).
Neither KOR/mice nor any virally injected group showed an
effect of U50,488 on locomotor activity (p  0.05) (Fig. 2c),
demonstrating that the restoration of KOR expression was
restricted.
We previously reported that injection of lenti-KOR or lenti-
KSA into the DRN restored U50,488-induced analgesia, leading
to an increase in warm water tail-flick latency (Land et al., 2008).
Two-way ANOVA showed a significant interaction (F(4,57) 

8.827, p  0.0001), and subsequent post hoc analysis demon-
strated that only KOR/ mice showed a significant increase in
their tail-flick latency 30 min after injection with U50,488 (15
mg/kg, i.p.) (KOR/, p 0.001). Neither KOR/mice with-
out viral injection nor any group receiving lentiviral injections
into the VTA showed an effect of U50,488 (p 0.05, all groups)
(Fig. 2d). As a positive control, we performed a tail-flick analgesia
test on KOR/ mice that had received lenti-KOR injected into
theDRN. A paired t test showed that the lenti-KOR injection into
the DRN restored U50,488-induced analgesia in these mice
(t(12) 
 4.409, p  0.001) (Fig. 2e). This demonstrated that the
restoration of U50,488 CPA in lenti-KOR VTAmice was not due
to viral diffusion to the nearby DRN.
After the behavioral analyses were concluded, mice were
killed, and immunohistochemistry (IHC) was performed to as-
sess KOR expression in the VTA. KOR-immunoreactivity (ir)
was evident in the VTA of wild-type mice, as well as KOR/
mice injected with lenti-KOR or lenti-KSA in the VTA, but not in
uninjectedKOR/mice (Fig. 2f). KOR-ir was not evident in the
VTA after lenti-KOR injection into the DRN (Fig. 2g), thus fur-
ther demonstrating that the aversion seen after DRN injection
was not due to viral diffusion to the VTA. KOR expression was
not seen outside of the VTA in mice injected intra-VTA with
either lenti-KSA or lenti-KOR (data not shown).
Selective restoration of KOR activation to VTA dopamine
neurons of KOR/mice rescues aversion in a
phosphorylation-dependent manner
Although the previous experiment demonstrated that KOR acti-
vation and phosphorylation within VTA neurons was sufficient
to support U50,488 CPA, it did not clarify which cell types are
required. To determinewhetherKOR expressionwithin dopami-
nergic neurons of the VTA alone was sufficient to support KOR-
CPA, we developed an adeno-associated double-floxed inverse
open reading frame (AAV-DIO) viral construct (Cardin et al.,
2009) directing expression ofGFP-taggedKORorKSA selectively
in Cre-expressing neurons (Fig. 3a; DIO-KOR-GFP or DIO-
KSA-GFP). The number of cells showing colocalization between
GFP-ir and immunoreactivity for tyrosine hydroxylase (TH-ir), a
selective marker for dopamine neurons, was significantly in-
creased in DATCre/ mice relative to DAT/ mice (Fig. 3b,c;
two-way ANOVA, main effect of genotype, F(1,43) 
 110.7, p 
0.0001), demonstrating selectivity of expression. Although WT
control mice showed a normal CPA to U50,488, DATCre/
KOR/ mice showed U50,488 CPA after intra-VTA injection
with DIO-KOR-GFP but not DIO-KSA-GFP (Fig. 3d; unpaired t
test, t(29)
 2.767, p 0.01). This demonstrates that KOR activa-
tion in VTA dopamine neurons alone is sufficient to support
CPA, but this requires an intact GRK3 phosphorylation site.
Expression of p38MAPK in dopamine neurons is selectively
required for KOR CPA
To test the hypothesis that p38MAPKactivation in dopaminergic
neurons is required for the aversive properties of KOR activation,
we generated a conditional knock-out of p38 MAPK in DAT-
expressing neurons, using a Cre-induced recombination of a
floxed p38MAPK allele (Bruchas et al., 2011). A subset of ani-
mals carried a floxed-STOP ROSA-YFP reporter allele to ensure
that Cre-induced recombination only occurred in dopamine
neurons. Subsequent IHC demonstrated that YFP highly coex-
pressedwith tyrosine hydroxylase (TH-ir)within theVTAonly in
Cre-expressing animals (Fig. 4a) but did not colabel with the 67
kDa isoform of glutamic acid decarboxylase, a marker for
GABAergic somata (Fig. 4b). TheDRN also contains dopaminer-
Figure4. ROSA-YFP reporter shows thatDAT-Cre selectively expresses indopaminergic neu-
rons. a, Representative IHC images showing that YFP-ir in an animal with DAT-Cre-directed
ROSA-YFP expression extensively colabels with TH-ir throughout the VTA, yet YFP expression
was absent in sections from mice lacking Cre: green represents YFP-ir; red represents TH-ir;
yellow represents double-label. b, Representative IHC images showing that YFP-ir in sections
from an animal with DAT-Cre-directed YFP expression in the VTA does not colabel with GAD67-
ir. Arrows point to GABAergic neurons. c, Representative IHC images showing that YFP-ir in an
animalwith DAT-Cre-directed YFP expression in the DRN colabelswith TH-ir but not TPH-ir. Left
panel, Imaged section of the DRN (modified from Paxinos and Franklin, 2008).
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gic neurons (Stratford and Wirtshafter,
1990; Hasue and Shammah-Lagnado,
2002; Fu et al., 2010), and we confirmed
that Cre-driven YFP expression colabeled
with TH-ir neurons in the A10c and
A10dc populations within the DRN.
However, no overlap was observed be-
tween YFP-ir cells and immunoreactivity
for tryptophan hydroxylase (TPH), a
marker for serotonergic neurons (Fig. 4c).
Experiments were performed on three ge-
notypes: WT (DAT/; p38/lox), Cre 
(DATCre/; p38/), and p38 CKODAT
(DATCre/; p38/lox). The Cre  mice
were used as controls to address any con-
cerns regarding potential reductions in
p38orDATexpression(Giros et al., 1996).
As expected, WT and Cre  mice
showed U50,488-induced CPA (Fig.
5a). However, p38 CKODAT mice
failed to show CPA to the drug-paired
context (one-way ANOVA, F(2,31) 

3.800, p  0.05; post hoc vs WT, t(31) 

2.366, p  0.05; post hoc vs Cre ,
t(31) 
 2.496, p  0.05) (Fig. 5a). These
results suggest that the aversive proper-
ties of KOR activation are dependent on
the expression of p38 MAPK in dopa-
minergic neurons.
We next tested mice with repeated ex-
posure to the rotarod performance assay,
a dopamine-dependent test of motor co-
ordination in which mice learn to avoid a negative outcome over
repeated trials (Zhou and Palmiter, 1995). p38 CKODAT mice
showed no deficit in this task, as demonstrated by a statistically
significant main effect of trial (Fig. 5b; two-way repeated-
measures ANOVA, F(8,36) 
 55.55, p  0.0001) and no effect of
genotype (F(2,36) 
 1.059, p 
 0.3573). Although a statistically
significant interaction was seen (F(16,36)
 2.098, p 0.01), post
hoc analyses showed no significant difference between the perfor-
mance of p38 CKODAT mice andWT (p 0.05) or Cre (p
0.05) mice during any trial. Indeed, p38 CKODAT mice showed
a slight trend toward improved performance relative toWT, sug-
gesting that p38 inactivation in dopamine neurons does not dis-
rupt basic motor learning and therefore is not grossly altering
dopamine neuron function.
To determine whether conditional knock-out of p38 af-
fected Pavlovian contextual learning, we measured cocaine CPP.
p38 CKODAT mice developed robust cocaine CPP, and there
was no significant difference between the three genotypes (one-
way ANOVA, F(2,25) 
 1.385, p 
 0.2688) (Fig. 5c). Locomotor
activity was recorded and analyzed during the cocaine condition-
ing sessions, and significant locomotor sensitization was evident
in all three genotypes (Fig. 5d), as demonstrated by a main effect
of training session (F(1,28) 
 52.12, p  0.0001), no interaction
(F(2,28)
 0.1836, p
 0.8333) and no effect of genotype (F(2,28)

1.314, p 
 0.2849). Further, post hoc analyses for all groups
showed a statistically significant increase in locomotor activity on
the secondday of cocaine administration relative to the first (WT:
t(28) 
 3.867, p  0.01; Cre : t(28) 
 3.863, p  0.01; p38
CKODAT: t(28)
 4.808, p 0.001). Because acute sensitization to
the locomotor effects of cocaine has been hypothesized to be
mediated by induction of glutamatergic LTP in dopaminergic
neurons (Borgland et al., 2006), these results further confirm that
effects of p38 inactivation are specific to aversion relating to KOR
activation and do not appear to reflect general deficits in dopa-
mine neuron function.
Conditional knock-out of p38 from dopamine neurons fails
to alter KOR-induced inhibition of dopamine release in vivo
To determine whether p38 MAPK was also required for the
inhibition of dopamine release, we used FSCV to measure sub-
second changes in the release of dopamine in anesthetized mice
(Fig. 6a). U50,488 (5 mg/kg, i.p.) inhibited dopamine release
evoked by MFB stimulation. U50,488 reduced evoked dopamine
release equivalently in both NAc core (54.5  4.2% inhibition
from baseline) and shell (50.7 2.3% inhibition from baseline)
of wild-type mice, but did not do so in KOR/ mice (Fig. 6b;
two-way ANOVA, main effect of genotype: F(1,16) 
 205.3, p 
0.0001).
Because there was no trend toward a main effect of NAc sub-
region on the inhibition of dopamine release (F(1,16) 
 0.9631,
p
 0.3410) and no interaction (F(1,16)
 0.006200, p
 0.9382),
time-resolved data collected from the NAc core and shell were
collapsed together for comparison betweenMFB and PPTg stim-
ulation. MFB stimulation allows for direct stimulation of the
fibers projecting to the NAc and minimizes the potential impact
of somatodendritic KOR activation, whereas PPTg stimulation
synaptically activates VTA neurons (Zweifel et al., 2009) andmay
reveal somatodendritic effects of KOR activation on dopamine
release in the NAc (Ford et al., 2006, 2007; Margolis et al., 2006;
Ehrich et al., 2014). Positioning of the stimulating electrodes as
shown (Fig. 6c) resulted in robust dopamine signal following
either MFB or PPTg stimulation (Fig. 6d,e, respectively, inset).
Release evoked by either MFB or PPTg stimulation was signifi-
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Figure 5. Conditional knock-out of p38 MAPK from dopaminergic neurons selectively blocks the aversive properties of KOR
activation. a, Preference scores show that p38 CKO DAT mice do not show U50,488 CPA, unlike WT and Cre littermates (n

12–20). *p 0.05 (Bonferroni post hoc after one-wayANOVA).b, Fall latency for each trial from rotarod performance assay shows
no effect of p38 CKO DAT (n
 10–16). c,WT, Cre, and p38 CKO DATmice all shownormal cocaine CPP (n
 8–11).d,WT, Cre
, and p38 CKO DATmice all shownormal acute locomotor sensitization to cocaine (n
 8–11). **p 0.01 (Bonferroni post hoc
after two-way ANOVA). ***p 0.001 (Bonferroni post hoc after two-way ANOVA).
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cantly inhibited by U50,488 (5mg/kg, i.p.); however, conditional
knock-out of p38 from dopamine neurons did not affect
U50,488-induced inhibition of dopamine release following either
MFB (Fig. 6d; unpaired t test, t(14)
 0.3018, p
 0.7673) or PPTg
(Fig. 6e; unpaired t test, t(18) 
 1.649, p 
 0.1166) stimulation.
Given the role of p38 MAPK in aversion
and the prediction that the inhibition of
dopamine release should be intrinsically
aversive (Wise and Bozarth, 1982; Ship-
penberg et al., 1993; Di Chiara and Im-
perato, 2008; Chefer et al., 2013; Tejeda et
al., 2013), the lack of effect of p38 dele-
tion on evoked dopamine release was a
surprise. This suggested that the aversive
effects of KOR activation were not caused
by either presynaptic or somatic inhibi-
tion of dopamine release within the NAc
and is consistent with our observations
that KOR-mediated aversion through se-
rotonergic neurons is independent from
inhibition of dopamine release.
Pharmacological inhibition of p38
MAPK by SB203580 fails to alter KOR-
induced inhibition of dopamine release
in vitro
To validate the results of the FSCV exper-
iments performed in vivo in transgenic
mice, we applied the selective p38 inhibi-
tor SB203580 in an in vitro slice FSCV as-
say. Similar to results obtained in vivo,
electrically evoked dopamine release de-
tected in NAc slices was significantly re-
duced by the KOR agonist U69,593 (1
M), and the inhibition was blocked by
pretreatment with norBNI (10 M)
(Fig. 7a,b). Bath application of 10 M
SB203580 failed to alter basal dopam-
ine release (two-way repeated-measures
ANOVA showed no main effect of
SB203580: F(1,14) 
 1.297; p 
 0.7794).
SB203580 also failed to alter either inhibi-
tion of dopamine release by U69,593 or
the reversal of inhibition by norBNI
(main effect of KOR drug: F(2,14)
 51.95;
p 0.0001; no interaction: F(2,14)
 1.067;
p 
 0.3576). Despite the lack of a signifi-
cant interaction, a post hocwas performed
to confirm that SB203580 had no effect on
U69,593-induced inhibition of dopamine
release (t(14) 
 0.7348, p  0.05). To de-
termine whether SB203580 had any effect
on the velocity of the inhibition of dopa-
mine release, we analyzed the slope of the
linear phase during U69,593 onset and
foundnodifference between the two (data
not shown: t test, t(14) 
 0.1010,
p 
 0.9210; vehicle 
 6.0  2.1,
SB203580
6.2 1.5).
Because both KOR activation and di-
rect p38 MAPK activation by anisomy-
cin have been shown to alter the rate of
dopamine uptake (Thompson et al.,
2000; Zhu et al., 2005), we analyzed the half-life (t1/2) of re-
leased dopamine to determine whether there was any effect of
either p38 MAPK inhibition or KOR activation in this assay
(Fig. 7c). No effect of U69,593 was found on t1/2 of released
dopamine (no main effect of KOR drug: F(2,14) 
 1.018, p 
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Figure 6. Conditional knock-out of p38MAPK from dopaminergic neurons fails to alter inhibition of dopamine release by U50,488
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doesnot significantly alter t1/2 inWT, Cre, or p38CKO
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ANOVA confirmed the lack of statistical significance).
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0.3745), which was also unaltered by
SB203580 (main effect: F(2,14)
 0.0003,
p
 0.9871). Despite the lack of a signif-
icant interaction, two post hoc analyses
were performed to confirm that
SB203580 had no effect on dopamine
uptake either with or without the pre-
sence of U69,593 (SB203580 or vehicle
alone: t(14)
 0.6755, p 0.05; U69,593:
t(14) 
 0.9288, p  0.05). These results
indicate that the KOR-induced inhibi-
tion of dopamine release in the NAc did
not require p38 activation either in vivo
or in vitro.
In vivo recording of VTA neuron firing
rates in freely moving mice
The lack of effect on evoked dopamine
release suggested that KOR activation of
p38MAPK produced aversion by a dif-
ferent effect on VTA neuron excitabil-
ity. Prior in vitro electrophysiological
studies have demonstrated that acute
KOR activation inhibits both presynap-
tic excitatory and inhibitory synaptic in-
puts to VTA dopamine neurons, as well
postsynaptically reducing firing rates by
activating outward potassium currents
(Margolis et al., 2003, 2006; Ford et al.,
2006, 2007). How VTA neuronal excit-
ability is affected by repeated KOR acti-
vation at the doses and schedules used
for conditioned place aversion is not clear from the in vitro
analysis. To determine how the dose of U50,488 that promotes
conditioned aversion in wild-type mice alters the firing of
dopamine neurons in a p38-dependent manner, we recorded
neural activity in the VTA of wild-type and p38 CKODAT in
unanesthetized, freely behaving mice. Drivable tetrodes were
implanted daily above the VTA (Fig. 8A) and lowered until
putative dopamine cells were identified that displayed an in-
hibitory response to the dopamine D2 receptor agonist quin-
pirole, as previously described (Zweifel et al., 2009, 2011).
Action potential waveforms of putative dopamine neurons
and basic firing properties of these cells did not differ between
control and p38 CKODAT mice (Fig. 8B–E).
On day 1, wild-type C57BL/6 male mice (control) and p38
CKODAT mice (CKO) were injected with saline following a 10
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Figure7. Pharmacological inhibitionof p38MAPKbySB203580 fails to alter KOR-mediated inhibitionof dopamine release recorded in thenucleus accumbensof amid-brain slice.a, Change from
baseline locally stimulated peak [DA] during baseline and following administration of 10M SB203580 or aCSF vehicle, 1M U69,593 and 1M norBNI. Each drug was bath-applied during the
interval signified by the bar. Inset, Diagram represents placement of bipolar stimulating electrode (red) and recording electrode (blue) during slice FSCV experiments (modified from Paxinos and
Franklin, 2008).b, Summary data show that the p38 inhibitor SB203580 (10M) did not significantly affect U69,593-induced inhibition of dopamine release (n
 8 slices from7 animals) (n.s., p
0.05, Bonferroni post hoc after two-way repeated-measures ANOVA), despite lack of interaction. Inset, Locally stimulated dopamine release during administration of SB203580 or vehicle, during
baseline (aCSF), U69,593, or U69,594 with norBNI. Calibration: 1 s, 2 nA. Arrow indicates stimulation. c, Clearance rates (T1/2) of evoked dopamine from peak during administration of 10 M
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 8 slices from 7 animals) (n.s., p 0.05, Bonferroni post hoc analysis after two-way repeated-measures ANOVA confirmed lack of
statistical difference).
Figure 8. In vivo recording of VTA dopamine neurons in wild-type littermate and p38 CKO DAT mice shows no significant
differences in baseline firing properties. A, Brain atlas diagram illustrating placement of tetrodes for control (black) and p38
CKO DAT (CKO) (red) mice. B, Average waveform of neurons responsive to quinpirole in control (black, N
 14) and CKO (red, N

8)mice.C, Baseline firing rate of quinpirole-sensitive neurons.D, Baseline burst rate of quinpirole-sensitive neurons.E, Percentage
spikes per burst of quinpirole-sensitive neurons.
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minbaseline recording period.VTAneurons did not significantly
change their firing rates (Fig. 9A,B). On the next 3 consecutive
days, mice were injected with U50,488 (5 mg/kg, i.p., U50-1,
U50-2, U50-3) following a 10 min baseline recording period to
mimic place aversion conditioning.Wewere surprised to see that
U50,488 injection did not significantly affect the average firing
rate of putative dopamine neurons on the first day of injection in
either control or CKO mice (Fig. 9A–C). On day 1, some cells
increased and some decreased their firing rates (Fig. 9D), which
resulted in no effect overall. However, on day 2 of U50,488, we
observed a significant decrease in firing of neurons in both con-
trol and p38 CKODAT mice (Fig. 9A–C; repeated-measures
ANOVA effect of day F(3,253)
 4.31; p 0.01). Enhanced inhib-
itory responses to U50,488 were a temporary adaptation in con-
trol mice (day 2 t(35) 
 2.53, p  0.05),
returning to day 1 levels of inhibition on
the third day of U50,488 (Fig. 9A,C). In
contrast to control mice, p38 CKODAT
mice demonstrated inhibition on day 2
(t(35)
 2.04, p 0.05) and day 3 (t(41)

2.03, p  0.05). p38 CKODAT mice
maintained an increased inhibitory re-
sponse on day 3, suggesting that p38
MAPK activation was responsible for
the adaptation (Fig. 9B,C). To confirm
the increased inhibitory response of
neurons to a subsequent dose of
U50,488 was dependent on KOR activa-
tion, we repeated our recordings in a
separate cohort of control mice but pre-
treated with the KOR antagonist nor-
BNI (10 mg/kg, i.p.) 50 min before
U50,488 administration on the first day.
Pretreatment with norBNI prevented
the enhanced inhibitory response to
U50,488 on the second day of adminis-
tration, confirming KOR dependence
(Fig. 9C).
p38MAPK activation stimulates GIRK
phosphorylation in VTA dopamine
neurons
The change in excitability noted in the
quinpirole-sensitive VTA neurons is con-
sistent with an effect of p38MAPK acti-
vation that we previously observed in
DRN neurons (Lemos et al., 2012). KOR
activation increases G-protein-gated in-
wardly rectifying potassium channel con-
ductance in both DRN and VTA neurons
(Margolis et al., 2003; Ford et al., 2006;
Lemos et al., 2012), and this likely results
in the reduced firing rates of the VTA
neurons. KOR activation of p38 MAPK
results in phosphorylation of these chan-
nels, which reduces their conduct-
ance (through an enhanced rate of
deactivation) (Ippolito et al., 2002). Pre-
venting this channel phosphorylation by
p38 CKO would result in the pattern of
sustained inhibition evident in the CKO
mice on day 3. To test the hypothesis
that KOR activation increases GIRK-
phosphorylation in VTA neurons, we used a phospho-selective
antibody previously shown to detect phospho-tyrosine 12 in Kir
3.1 (Ippolito et al., 2005). Treatment with the KOR agonist
U50,488 was shown to increase pY12-Kir 3.1/GIRKp-ir in the
dorsal raphe nucleus in a p38-dependent manner (Lemos et al.,
2012).
In the current study, we examined GIRKp-ir expression in
ROSA26YFP-reporter labeled dopaminergic neurons of the
VTA. InDAT-cremice, ROSA26YFP expression was restricted to
dopaminergic neurons of the VTA (Fig. 10A). Basal GIRKp-ir
was low, but substantially increased following repeated U50,488
treatment (20 mg/kg i.p., once daily 3 d; Fig. 10A). Basal
GIRKp-ir was also low inVTA sections fromp38CKODATmice
pretreated with saline; however, repeated U50,488 treatment in-
Figure 9. A, B, Change in firing rate following injection of saline or U50 on consecutive days for control (A) and CKO (B) mice
(control saline, N
 31; U50 d 1, N
 21; U50 d 2, N
 26; U50 d 3, N
 35; p38CKO DAT saline, N
 33; U50 d 1, N
 40; U50
d 2,N
 35; U50 d 3,N
 41). Data are presented as the average change in firing rate (Hz) from a 10min baseline period. Data are
binned into 10 min blocks. C, Average change in firing rate during the last 40 min following injection of saline or U50,488 across
groups. *p 0.05, relative to corresponding saline (Bonferroni post-test). D, Change in firing rate following injection of U50 on
successive days. Micewere pretreatedwith an injection of norBNI 50min before U50 on day 1 (U50 d 1,N
 22; U50 d 2,N
 24).
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creased GIRKp-ir only in nondopaminer-
gic neurons (Fig. 10A). The number of
dopaminergic neurons coexpressing
GIRKp-ir was quantified in a blinded
manner (Fig. 10B). The percentage of
GIRKp-positive YFP-positive cells in-
creased in control mice expressing wild-
type levels of p38 (U50(3d) treated: 63
1.5%, saline vehicle (3d): 35  7%). The
U50,488-induced increase in colocaliza-
tion was not evident in p38 CKODAT
conditional knock-out mice lacking p38
in dopaminergic neurons (U50(3d): 39
4%, Sal(3d): 32 3%, two-way ANOVA,
F(1,40) 
 4.91, main effect of treatment
p
 0.0008; genotype p
 0.0074; interac-
tion p 
 0.0325, Bonferroni post hoc sig-
nificant (t(40) 
 4.521, p  0.001) for
control saline vs control U50, n 
 3 or 4
slices per animal, 2 or 3 animals per group;
Figure 10A,B). The increase in GIRK
channel phosphorylation by KOR acti-
vated p38 is consistent with the suppres-
sion of U50,488 inhibitory effects on
dopaminergic neurons firing observed on
day 3, but how that results in CPA is not
yet clear.
Discussion
The principal findings of this study are
that KOR activation of p38 MAPK
within the VTA is required for the aver-
sive properties of KOR activation. Sec-
ond, the aversive properties of KOR
activation are rescued in KOR/ mice
by viral restoration of KOR signaling to
VTA dopamine neurons. This restora-
tion is dependent on the phosphoryla-
tion of KOR at serine 369, which is
required for p38 activation but not for
activation of ERK (Land et al., 2008).
Third, the aversive properties of KOR
activation are dependent on the expres-
sion of p38 in dopaminergic neurons,
but the ability of KOR agonists to in-
hibit dopamine release is not dependent
on p38 MAPK activation within dopa-
minergic neurons. Fourth, KOR activa-
tion has complex, time-dependent effects on VTA neuron
firing rates, which likely involves p38 MAPK-induced GIRK
phosphorylation and regulation of excitability. Together,
these findings suggest that activation of p38 MAPK by KOR in
dopaminergic neurons is required to elicit the aversive prop-
erties of KOR agonists, and this process occurs independently
of KOR’s ability to inhibit dopamine release.
KOR agonists induce dysphoria in humans (Pfeiffer et al., 1986),
aversion in animalmodels (Shippenberg andHerz, 1986), and inhi-
bition of dopamine signaling in the NAc in animal models (Di Chi-
ara and Imperato, 1988; Spanagel et al., 1990). As such, it has been
proposed that these effects are causally related: the aversive proper-
ties of KOR agonists are mediated by inhibition of NAc dopamine
signaling (Di Chiara and Imperato, 1988; Spanagel et al., 1990;
Tejeda et al., 2012; Carroll and Carlezon, 2013). However, this hy-
pothesis and the data that support it are based on correlation, and
dopamine receptor antagonists are not consistently aversive. The
hypothesis was driven by the then-prevalent theory that NAc dopa-
mine signaling mediated hedonic responses (Wise and Bo-
zarth, 1982), whereas current theories focus more on the role
of dopamine signaling in effort (Salamone et al., 2003), reward
prediction error (Schultz, 1998), reinforcement, or incentive
salience (Montague et al., 2004). The precise role played by
reduction of dopamine in these models is varied and not en-
tirely clear, as the experiments performed have focused on
pharmacological or behavioral responses, which increase NAc
dopamine or directly affect dopamine signaling at or down-
stream of the receptor. We confirm that KOR activation does
inhibit dopamine release in the nucleus accumbens; however,
KOR activation has other actions in the VTA-reward circuit
Control + Sal Control + U50 
GIRKp-ir 
YFP-ir 
A 
B 
p38αCKODAT + U50 p38αCKODAT + Sal 
50 μm 
Figure 10. U50,488 increases VTA dopamine neuron GIRKp-ir in a p38MAPK-dependentmanner. A, Representativemerged
fluorescent images (40) illustrating the increased amount of GIRKp-ir (green fluorescence) in YFP-reporter-labeled dopamine
neurons (red fluorescence) of the VTA following 3 d of U50,488 treatment, giving rise to yellow signal when colocalized. Scale bar,
50m. B, Quantification of the percentage of YFP-ir putative dopamine neurons of the VTA also positive for GIRKp-ir. In control
mice that expressedwild-type levels of p38, U50,488 treatment significantly increased thepercentage (SEM)of colabeled cells
relative to saline vehicle, but this effect of U50 was absent in p38CKO DAT mice lacking p38 in the YFP-ir cells. ***p 0.05,
interaction (two-way ANOVA). N
 3 or 4 slices per animal, 2 or 3 animals per group. n.s., Not significant.
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and aversion seems unlikely to be a consequence of a simple
reduction in dopamine transmission.
Reinterpretation of the KOR/dynorphin aversive circuit
Previous experiments have focused on the role of a single mono-
aminergic circuit as mediating the aversive properties of KOR
activation, predominately via effects on dopamine signaling
(Shippenberg et al., 1993) or via effects on serotonergic signaling
(Land et al., 2008; Bruchas et al., 2011). Other experiments have
focused on the ability of KOR agonists to alter glutamatergic or
GABAergic input onto dopamine neurons (Margolis et al., 2005;
Polter et al., 2014). In wild-type KOR/ animals, p38 MAPK
activation is necessary in both classes of neurons; further, KOR
activation is necessary in the NAc and DRN (Land et al., 2008;
Bruchas et al., 2011), the VTA (present results), and the mPFC
(Tejeda et al., 2013). This implies the actions of KOR at multiple
sites in the neuronal circuit, requiring either simultaneous or
feedforward activation of KORs and subsequently of p38 MAPK
in an extended circuit to cause aversion. The current results sug-
gest that KOR-mediated aversion is encoded in a complex chain
of neuronal processing events involving multiple brain regions
and that it can be disrupted by breaking any one of the links.
Alternately, KOR activation in different circuits could mediate
different modes of aversion, operationally mediated by disparate
mood states, such as anhedonia, depression, dysphoria, or anxi-
ety. TheCPAmodel used in this and other studiesmay be incapable
of parsing between these different states. Future experiments could
focus on trying to distinguish between these different states to deter-
mine whether each is disparately affected by manipulation of KOR
and p38MAPK activation in these circuits.
Potential downstream effects of p38MAPK in
dopaminergic neurons
Although the results presented in this study strongly implicate
p38MAPK-mediated signaling in the VTA dopaminergic neu-
rons, this kinase has a broad range of potential substrates
(Cuadrado and Nebreda, 2010). In serotonergic neurons, KOR
activation of p38MAPK caused translocation of the serotonin
transporter (SERT, SLC6A4) from an intracellular, endosomal
compartment to the cell surface to increase the rate of serotonin
reuptake (Bruchas et al., 2011; Schindler et al., 2012). KOR acti-
vation of p38 MAPK could potentially have affected the DAT
(SLC6A3) because in vivo administration of the  agonist
U69,593 increased dopamine uptake (Thompson et al., 2000);
however, p38 MAPK did not affect dopamine uptake in DAT-
expressing COS cells (Lin et al., 2003), and we did not observe an
effect of p38 activation on dopamine uptake in the present study.
In contrast, repeated KOR activation produced p38-
dependent effects on VTA dopamine neuron firing rates in freely
moving, unanesthetized mice in the present study. Prior analyses
usingwhole-cell voltage-clampmethods demonstrated that KOR
regulates both presynaptic and postsynaptic currents (Margolis
et al., 2003, 2005, 2006; Ford et al., 2006, 2007). Consistent with
the in vitro findings, we observed a complex response following
acute U50,488 administration on day 1, with some cells increas-
ing and some cells decreasing their firing rates. The net effect on
excitability would be expected to depend on the balance between
changes in excitatory, inhibitory, and postsynaptic effects of KOR
activation. This balance shifted on day 2, and the p38 MAPK-
sensitive effect was only evident after repeated KOR stimulation,
which is consistent with prior demonstration that p38 activation
requires sustained KOR activation and arrestin recruitment
(Bruchas et al., 2006, 2007a, 2011). Although this is somewhat
controversial, KOR activation may acutely increase the
G-protein-gated inwardly rectifying potassium channel in VTA
dopamine cells (Margolis et al., 2003; Ford et al., 2006), as it does
in other neurons. Activation of GIRK would hyperpolarize the
membrane and might contribute to the inhibition of neuronal
firing observed in these freelymovingmice. GIRK is a hetrotetra-
meric potassium channel containing a pair of highly conserved
tyrosine residues in the amino termini of its Kir3.1 and Kir3.4
components (Rogalski et al., 2000). Tyrosine phosphorylation of
these residues inactivates the channel by increasing the rate of
G dissociation, asmeasured in transfected cells (Ippolito et al.,
2002, 2005). Kappa receptor activation of p38 MAPK stimulates
GIRK phosphorylation by activating an src-like kinase in spinal
cord (Rogalski et al., 2000; Clayton et al., 2009), and GIRK cur-
rents are similarly inhibited by stress-induced KOR activation of
p38 MAPK in DRN neurons (Lemos et al., 2012). The present
study suggests that stress-induced aversion results from sustained
dynorphin activation of KOR, causing arrestin-dependent p38
MAPKphosphorylation of Y12-Kir3.1. The change in postsynap-
tic effects would alter the balance of excitatory and inhibitory
responses, but exactly how this results in the behavioral response
is not yet clear. What is clear is that p38MAPK signaling down-
stream of KOR activation impacts the phosphorylation status of
at least one protein, which is likely just a sample of many post-
translational modifications that are altered by activation of this
kinase. Given the broad substrate range of p38MAPK, it is very
likely that the ability of KOR activation tomediate aversive effects
is through changes in the phosphorylation status and function of
these proteins that operate independently of detectable changes
in dopamine release.
These experiments suggest that p38MAPK in dopamine neu-
rons plays a key role in the aversive properties of KOR. The ac-
tions of dynorphin and KOR-induced activation of p38 MAPK
have been proposed to mediate the dysphoric component of
stress (Land et al., 2008) and play a key role in depressive behav-
iors (Bruchas et al., 2011). Understanding the cellular mecha-
nisms of these behaviors provides novel insights into the stress
response. In addition, results suggesting that the dysphoric effects
of KOR agonists require arrestin-dependent, p38 MAPK signal-
ing supports the hypothesis that a G-protein-biased KOR agonist
might be an analgesic with low abuse potential (Chavkin, 2011).
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